switching between semaglutide and tirzepatide weight-loss medications Why You Might Tolerate One

[DOI] [PubMed] [Google Scholar] Nakazaki M, Crane A, Hu M, Seghers V, Ullrich S, Aguilar-Bryan L, Bryan J

Bril, V

Key takeaways: Retatrutide reduced moderate-to-severe OSA severity by up to 36.1 events per hour (60.6%) from a baseline of 58.6 events per hour

doi: 10.18388/abp.2009_2452 36 KimS.HwangJ

Blue Shield of California Provided insights into market-informed recommendations for continued improvement of their rotational leadership programs with respect to recruiting, onboarding, curriculum, retention and placement

Statements Author contributions RA-T: Conceptualization, Investigation, Writing original draft, Writing review & editing